Foamix于2003年1月19号在以色列成立。该公司是一家临床阶段制药公司专注于开发和商业化公司专有的泡沫米诺环素治疗痤疮,脓疱疮等皮肤状况。该公司的主导候选产品,fmx101为中度至重...查看全文
牛唐2018-07-28 22:07
$Foamix(FOMX)$ FMX101是外用的minocyline,用于治疗痤疮,预计今年下半年或明年上半年申报NDA,如果获批的话,将是首个获批的米诺环素外用药查看全文
$Foamix(FOMX)$ 8-K - Current report Filed: 2018-03-29 AccNo: 0001178913-18-001025 Size: 27 KBItem 5.08: Shareholder Nominations Pursuant to Exchange Act Rule 14a-11Item 8.01: Other Events 网页链接
$Foamix(FOMX)$ 内部交易: 2018-03-02,VP Drug Development,Elliott Russell P. ,卖出,817普通股, $6.14
$Foamix(FOMX)$ 内部交易: 2018-03-01,CEO,Domzalski David ,卖出,66普通股, $5.95
$Foamix(FOMX)$ 10-K/A [Amend] - Annual report [Section 13 and 15(d), not S-K Item 405] Filed: 2018-03-01 AccNo: 0001178913-18-000738 Size: 8 MB 网页链接
$Foamix(FOMX)$ 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] Filed: 2018-02-27 AccNo: 0001178913-18-000707 Size: 8 MB 网页链接
$Foamix(FOMX)$ 美东时间 2018-02-27 盘后 披露财报,预期EPS -0.45 网页链接
$Foamix(FOMX)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2018-02-14 AccNo: 0000930413-18-000475 Size: 105 KB 网页链接
$Foamix(FOMX)$ 美东时间 2018-02-20 盘后 披露财报,预期EPS -0.45 网页链接
$Foamix(FOMX)$ SC 13G - Statement of acquisition of beneficial ownership by individuals Filed: 2018-02-13 AccNo: 0001178913-18-000519 Size: 86 KB 网页链接
$Foamix(FOMX)$ SC 13G - Statement of acquisition of beneficial ownership by individuals Filed: 2018-02-13 AccNo: 0001178913-18-000517 Size: 81 KB 网页链接